can103
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 11, 2022 (NCT05447494)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta-glucocerebrosidaseSupplementation
GBA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05447494 | Phase 1/Phase 2 (Phase 2) | Jul 11, 2022 | CANbridge Life Sciences Ltd., Chinese Academy of Medical Sciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CANbridge Life Sciences Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1